These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30426333)

  • 1. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG; Kuwabara M; Borghi C
    Drugs; 2018 Nov; 78(17):1783-1790. PubMed ID: 30426333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Seleme VB; Marques GL; Mendes AEM; Rotta I; Pereira M; Júnior EL; da Cunha CLP
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):165-180. PubMed ID: 32710438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Nebivolol Pharmacology and Clinical Evidence.
    Fongemie J; Felix-Getzik E
    Drugs; 2015 Aug; 75(12):1349-71. PubMed ID: 26177892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
    Paton DM
    Drugs Today (Barc); 2017 Jan; 53(1):19-26. PubMed ID: 28387384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M; Gupta Y; Jain S; Vardas P
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
    Toblli JE; Cao G; Casas G; Mazza ON
    Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension.
    Sander GE; Fernandez C; Giles TD
    Expert Rev Cardiovasc Ther; 2016; 14(5):563-72. PubMed ID: 26986445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
    Vitale C; Marazzi G; Iellamo F; Spoletini I; Dall'Armi V; Fini M; Volterrani M
    Int J Cardiol; 2012 Mar; 155(2):279-84. PubMed ID: 22078979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.
    Ishak J; Rael M; Punzi H; Gradman A; Anderson LM; Patel M; Ali S; Ferguson W; Neutel J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):143-149. PubMed ID: 29105958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
    Battise D; Boland CL; Nuzum DS
    Ann Pharmacother; 2019 Apr; 53(4):402-412. PubMed ID: 30449127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol: a new antihypertensive agent.
    Gray CL; Ndefo UA
    Am J Health Syst Pharm; 2008 Jun; 65(12):1125-33. PubMed ID: 18541682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.